Diseases of the Esophagus
P1.116. Comparison Between Nivolumab + Ipilimumab, FOLFOX, and Nivolumab + FOLFOX Therapy as First-Line Therapy for Cisplatin-Unfit Advanced Esophageal Squamous Cell Carcinoma
Abstract Topic Esophageal Cancer: Non-Surgical Treatment of Esophageal Cancer Background Nivolumab plus platinum-based chemotherapy and nivolumab plus ipilimumab (Nivo+Ipi) therapy are standard first-line treatments for advanced esophageal squamous cell carcinoma (ESCC). However, patients with renal or cardiac dysfunction and elderly patients might be unfit for cisplatin-containing regimens. Therefore, leucovorin, 5-FU, and oxaliplatin (FOLFOX), Nivo+Ipi, and nivolumab plus FOLFOX (Nivo+FOLFOX) therapy might be alt …